BTM-3566

BTM-3566 is an oral small molecule from Bantam Pharmaceutical. An oral small molecule that activates the mitochondrial protease OMA1, which cleaves OPA1 and DELE1 and switches on the integrated stress response, leading to apoptosis of tumour cells. Its furthest stage is phase 1, for relapsed or refractory mature B-cell lymphomas (initial focus DLBCL) and advanced solid tumours. ClinicalTrials.gov registers it in 2 studies linked below. Whether it works in people has not been established unless a trial below reports it.